The Conversation (0)
International Stem Cell announced its subsidiaries Lifeline Cell Technology and Lifeline Skin Care expanded their manufacturing operations, OEM business, and product lines.
International Stem Cell (OTCQB:ISCO) announced its subsidiaries Lifeline Cell Technology and Lifeline Skin Care expanded their manufacturing operations, OEM business, and product lines.
As quoted in the press release:
“ISCO was one of the first stem cell biotech companies to build a business model in which revenue-generating subsidiaries operate under a parent R&D company. This not only decreases cash burn while conducting our Parkinson’s disease clinical trial, but gives us more confidence in ISCO’s future,” commented Russell Kern, PhD, Executive VP and Chief Scientific Officer of ISCO.
Lifeline Cell Technology LLC, a research products business which develops, manufactures, and commercializes human cell culture products, expanded and improved its media manufacturing operation by doubling the size of clean rooms, as well as the cell culture media production capacity.
Click here to read the full press release.
Source: globenewswire.com